LLY is trading at $1097.95 (+9.42%) following a Q4 2025 earnings beat driven by a 43% surge in revenue to $19.3 billion, fueled by massive demand for Mounjaro and Zepbound.
- The company issued upbeat FY2026 guidance with revenue projected at $80–83 billion and EPS of $33.50–35.00, far exceeding previous market forecasts.
- LLY is demonstrating significant relative strength, outperforming a mixed market and a decline in rival Novo Nordisk while the NASDAQ fell 0.5%.